A bench comprising Chief Justice Dipak Misra and Justices A M Khanwilkar and D Y Chandrachud said that it had already dealt with the issue in its earlier order passed in October 2016 and there was not question of recalling the same.
"We are not inclined to recall the order," the bench said.
Senior advocate Colin Gonsalves, appearing for petitioner S P Shukla, said that the plea be revived as the PSUs are not functioning and the government was still procuring vaccines from private firms at higher rates.
The court passed the order after the submissions made by senior advocate Colin Gonsalves, who said on behalf of the petitioner that the situation has not improved and the petition was disposed of without taking note of the ground situation.
In its order on October 10, 2016, the apex court had noted that the government has not only taken substantial steps towards reviving the dysfunctional institute by incurring considerable expenditure but some of the institutes had already gone into production.
The petitioner had sought a direction for appointment of an expert committee "that would look into the problems of the ailing institutes and suggest a revival plan so that the critically required vaccines are neither in short supply nor is the government dependent upon private producers for supply."
The vaccines including BCG which is primarily used against tuberculosis, DPT which is used for diphtheria, pertussis (whooping cough) and tetanus, DT which protects young children from diphtheria, tetanus, and whooping cough and TT, the tetanus vaccine, he had said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
